Repros Therapeutics back on NASDAQ 

Repros Therapeutics Inc. has been given the green light to begin trading on the NASDAQ Capital Market, but The Woodlands company isn’t completely out of the woods yet.

Repros (NASDAQ: RPRX) has until May 5 to meet the requirements for listing on the exchange, including having a minimum bid price and market value of publicly held shares of at least $1 million. Net income from continuing operations must total $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years.

Joseph Podolski, president and chief executive officer, said in a statement that the ability to remain a NASDAQ-listed company gives Repros “the greatest flexibility” as it considers financing options going forward.

Repros was hit with a second delisting notice from NASDAQ last September stating that the company had until Dec. 14 to comply with the requirements.